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Can corneal pannus with trachomatous
inflammation – follicular be used in
combination as an improved specific
clinical sign for current ocular Chlamydia
trachomatis infection?
Tamsyn Derrick1* , Martin J. Holland1, Eunice Cassama2, Rod Markham-David1, Meno Nabicassa2, Michael Marks1,
Robin L. Bailey1 and Anna R. Last1
Abstract
Background: Trachoma is a blinding disease caused by conjunctival infection with Chlamydia trachomatis (Ct).
Mass drug administration (MDA) for trachoma control is administered based on the population prevalence of the
clinical sign of trachomatis inflammation – follicular (TF). However, the prevalence of TF is often much higher than
the prevalence of Ct infection. The addition of a clinical sign specific for current ocular Ct infection to TF could save
resources by preventing unnecessary additional rounds of MDA.
Methods: Study participants were aged between 1–9 years and resided on 7 islands of the Bijagos Archipelago,
Guinea Bissau. Clinical grades for trachoma and corneal pannus and ocular swab samples were taken from 80
children with TF and from 81 matched controls without clinical evidence of trachoma. Ct infection testing was
performed using droplet digital PCR.
Results: New pannus was significantly associated with Ct infection after adjustment for TF (P = 0.009, OR = 3.65
(1.4–9.8)). Amongst individuals with TF, individuals with new pannus had significantly more Ct infection than
individuals with none or old pannus (75.0 % vs 45.5 %, Chi2 P = 0.01). TF and new pannus together provide a highly
specific (91.7 %), but a poorly sensitive (51.9 %) clinical diagnostic test for Ct infection.
Conclusions: As we move towards trachoma elimination it may be desirable to use a combined clinical sign (new
pannus in addition to TF) that is highly specific for current ocular Ct infection. This would allow national health
systems to obtain a more accurate estimate of Ct population prevalence to inform further need for MDA without
the expense of Ct molecular diagnostics, which are currently unaffordable in programmatic contexts.
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Background
Trachoma is the most common infectious cause of blind-
ness worldwide and is initiated by conjunctival infection
with Chlamydia trachomatis (Ct). Children living in
trachoma-endemic communities suffer repeated infections
with Ct, which manifests as a follicular conjunctivitis
(trachomatous inflammation – follicular (TF)), often
accompanied by papillary inflammation (trachomatous
inflammation – intense (TI)). Repeated Ct infections can
result in fibrosis and scarring of the tarsal plate, leading
to in-turning of the eyelashes (trichasis), abrasion of
the cornea and eventually blindness. It is currently esti-
mated that ~21.4 million people have active trachoma
[1], many of whom will go on to develop the scarring
sequelae that can lead to blindness.
The World Health Organization (WHO) aims to achieve
global elimination of trachoma as a public health problem
by the year 2020 through implementation of the “SAFE
strategy” (Surgery for trichiasis, Antibiotics for Ct infection,
Facial cleanliness and Environmental improvements to pre-
vent infection) [2]. When the baseline prevalence of TF in
1–9 year olds (TF1–9) is between 10–29 % the WHO rec-
ommends that 3 years of annual mass drug administration
(MDA) with Azithromycin should be delivered, extending
to 5 years when TF1–9 is ≥30 %. After 3 or 5 years of
MDA, impact surveys should be conducted before decid-
ing whether to continue or stop treatment [3]. MDA
should be conducted alongside the complementary S, F
and E activities. To meet elimination targets, TF1–9 is rec-
ommended to be below 5 % at the district level. If a district
has TF1–9 between 5–10 %, within-district communities
should be assessed and treated separately by the same prin-
ciples and F and E should continue.
The use of TF as a clinical sign for Ct infection can how-
ever be misleading. In low prevalence areas there is dis-
cordance between the prevalence of TF and Ct infection
[4–7], particularly after the introduction of MDA [8–10].
Clearance of TF lags behind the clearance of Ct infection
on both individual and population levels [8, 11, 12]. It is
thought that other chlamydial species and non-chlamydial
bacteria can contribute to the presence of TF in low-
prevalence settings, although the impact of these infec-
tions on scarring development is unclear [13–17].
These observations have led to the suggestion that
unnecessary additional rounds of MDA may be deliv-
ered by resource poor national eye health programs.
This was illustrated by a recent study in The Gambia,
where after one round of MDA no ocular infections
with Ct were detected in the 1–9 yr olds in the com-
munities under study. This enabled a premature halt
to the three year treatment regime in all communities
in that treatment arm [18]. Follow up at 3 years
showed that TF and Ct infection prevalence were
equivalent between communities where MDA ceased
after a single round of treatment and in those that had
received MDA for 3 years [18]. There are significant
costs associated with molecular testing for Ct however,
such that cost savings may only be achieved if testing
just a sample of children in each census area or in a
sample of census areas [19]. Implementation of a sim-
ple low-cost Ct diagnostic assay that can be used in
regional health care facilities to obtain Ct infection
population prevalence data is desirable, however test-
ing is currently confined to expensive commercial plat-
forms, which without subsidies or donations are not
feasible in operational settings.
Alternatively, extra information relating to the pres-
ence of ocular Ct infection in the community could be
ascertained by the inclusion of additional clinical signs
that are more sensitive or specific for current ocular
infection with Ct, such as corneal pannus. Pannus is the
sub-epithelial neovascularization of the peripheral cor-
nea. Corneal pannus was once one of three cardinal clin-
ical signs considered to be essential for the diagnosis of
trachoma (alongside “granulations” (follicles) and “con-
junctival scarring”) [20–22], however it has now been
discarded in the routine diagnosis of trachoma and was
not included in the WHO simplified grading system
[23]. It was noted that corneal pannus was rarely seen
independently and was more often seen alongside folli-
cles or scarring [20], suggesting that pannus is rarely
non-specific and that its accompaniment to the two
other signs of trachoma could indicate the presence of
Ct infection. In this small-scale study we have revisited
the utility of pannus as a diagnostic tool that might
increase the concordance of clinical signs and current
ocular Ct infection.
Methods
Ethical, consent and permissions
The study was conducted in accordance with the declar-
ation of Helsinki and was approved by the Ethics com-
mittee of the London School of Hygiene and Tropical
Medicine, The Gambian Government/Medical Research
Council Unit and the Comité Nacional de Ética em
Saúde of Guinea Bissau. Written informed consent was
obtained from a parent or guardian prior to a partici-
pant’s enrollment in the study.
Clinical sample collection and study design: case control
Samples were collected from children aged from 1 to
9 years residing on 7 islands of the Bijagos Archipelago,
Guinea Bissau, 6 islands of which were trachoma treat-
ment naïve at the time of sample collection. Children
were screened for clinical signs of trachoma by a trained
clinician using the WHO simplified trachoma grading
system [23] and the WHO 1981 FPC trachoma grading
system [24]. Individuals presenting with follicular scores
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of “F2” or “F3” using the FPC system were equivalent to
“Trachomatous Inflammation – Follicular (TF)” using
the simplified system and were defined as “TF cases”.
Individuals with no clinical signs of follicles (F0), papil-
lary hypertrophy (P0) or conjunctival scarring (C0) were
enrolled as “controls” and were matched to TF cases by
age, gender and village. Pannus was graded in all TF
cases and controls enrolled in the study as not present,
new (active neovascularization) or old (empty or scarred
vessels). Macro photographs were taken of the edge of
the cornea using a Nikon D60 SLR camera with a VR
AF-S micro Nikkon 105 mm 1:2.8G ED lens. In this
study we evaluated the use of corneal pannus as a clin-
ical sign for Ct infection using field observed grades,
analogous to how it would be implemented by national
trachoma control programmes.
Two conjunctival samples were taken from the left
upper tarsal conjunctiva of each participant with Dacron
swabs (Puritan) using standard methodology [10, 25].
Swabs were stored in RNAlater (Life technologies) and
kept in a cold chain in the field before subsequent stor-
age at −80 °C. The two swabs from each individual were
pooled for RNA and DNA extraction, which was car-
ried out using Norgen total RNA and DNA purification
kits following the manufacturers instructions (Norgen
Biotek).
Molecular testing for Chlamydia trachomatis
Droplet-digital PCR (ddPCR) was used to diagnose Ct
infection, as described previously [26, 27] with the fol-
lowing modifications. Forward and reverse primers were
used at 0.9 μM and probes were used 0.2 μM. Eight
microlitres of sample DNA was added to each 20 μl re-
action. An initial diagnostic assay detecting Ct plasmid
and human RPP30 endogenous control was carried out
on all samples. Ct chromosomal gene omcB and plasmid
DNA were then quantified in positive samples to deter-
mine Ct load. Primer and probe sequences are described
elsewhere [27]. Thermal cycling conditions were as fol-
lows: 95 °C hold for 10 min, followed by 40 cycles of
95 °C for 10 s and 60 °C for 20 s with a final hold of
98 °C for 12 min. ddPCR was performed on a Bio-Rad
QX100 Instrument and data were collected using
Quantalife software (Bio-Rad). Copy number was calcu-
lated in R using previously published scripts [26].
Statistical analysis
Data were analysed in R (www.R-project.org). Multivari-
able logistic regression was performed with Ct infection
as a binary outcome and clinical signs of TF and pannus
were included as independent variables. Age and gender
were included a priori.
Results
Clinical phenotypes of study participants are shown in
Table 1. Eighty individuals had TF, of whom 36 (45 %)
had new pannus. Amongst individuals with TF, individ-
uals with new pannus had significantly more Ct infection
than individuals with none or old pannus (75.0 % vs
45.5 %, Chi2 P = 0.01). Nine of the 81 controls (11.1 %)
and 2 of the 5 Ct positive controls had new pannus.
Representative photographs of pannus grades are shown
in Fig. 1. Chlamydial load increased with TF grade (data
not shown), but there was no apparent relationship be-
tween pannus and Ct load (Table 1).
In multivariable logistic regression analysis TF was
strongly associated with Ct infection (P = 1.16 x 10−7,
OR = 18.17 (6.73–59.5)). New pannus was independ-
ently associated with Ct infection after adjustment for
TF (P = 0.009, OR = 3.65 (1.4–9.8)). Old pannus was
not associated with Ct infection (P = 0.859, OR = 0.89
(0.23–3.26)) (Table 2). Exclusion of the 31 individuals
from the MDA treated island did not significantly change
the results of the regression analysis; TF (P = 3.83 x 10−6,
OR = 13.56 (4.83–45.7)) and new pannus (P = 0.01, OR =
4.04 (1.43–11.96)) remained significantly associated with
current Ct infection (data not shown).
We investigated the sensitivity and specificity of new
pannus and TF as a diagnostic clinical sign for Ct infec-
tion. TF was more sensitive than new pannus (90.4 % for
TF v 55.8 % for new pannus), whereas new pannus was
more specific than TF (69.7 % for TF v 85.3 % for new
pannus). The sensitivity of using new pannus and TF
together to diagnose Ct infection (excluding individuals
presenting with new pannus without TF, or TF without
new pannus) was 51.9 % and the specificity was 91.7 %
Table 1 Clinical phenotypes of study participants
Controls TF cases
Total 81 80
% Female 58 % 58.75 %
Median age (IQRb) 4 (3–6) 4 (2–6)
Ct positive (%) 5 (6.2 %) 47 (58.8 %)
Ct loada (IQRb) 345 (42–1077) 4600 (656–16462)
No pannus 55 34
Ct positive (%) 2 (3.6 %) 15 (44.1 %)
Ct loada (IQRb) 36672 (18509–54836) 4500 (1006–6112)
Old pannus 17 10
Ct positive (%) 1 (5.9 %) 5 (50 %)
Ct loada (IQRb) 1078 41250 (432–46750)
New pannus 9 36
Ct positive (%) 2 (22 %) 27 (75 %)
Ct loada (IQRb) 31 (25–36) 6800 (642–16462)
aCt load =median omcB copies/swab in samples positive for Ct DNA by ddPCR
bIQR = Inter-quartile range
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(Table 3). TF and new pannus together had the highest
positive predictive value (PPV) (75 %) and a good nega-
tive predictive value (NPV) (80 %).
Discussion
We have reported the performance of new pannus in
combination with TF as a clinical diagnostic test for ocular
Ct infection. New pannus was independently associated
with Ct infection after adjustment for TF, suggesting that
use of the two clinical signs together might increase the
likelihood of detecting Ct positive individuals. The pres-
ence of TF and new pannus together was a more specific
diagnostic test for Ct infection than either alone but it was
much less sensitive; therefore use of this combined clinical
sign in a trachoma control programme is likely to under-
estimate the prevalence of Ct infection.
The performance of TF alone as a clinical diagnostic
test for Ct infection in these samples was perhaps over-
inflated by the study design. A population-based survey
carried out on four other treatment-naïve islands of the
Bijagos Archipelago in Guinea Bissau in 2012 found that
in 1–9 year olds, the prevalence of TF was 22 % and the
prevalence of Ct infection was 25 % [25]. This present
study had a case–control design and participants were
enrolled on the basis of clearly defined clinical pheno-
types, therefore the likelihood of individuals with TF
having Ct infection was high. These are limitations of
this study and in order to assess the use of new pannus
and TF in combination as a proxy for current Ct
infection in an elimination context this experiment
should be repeated in a larger population-based survey
in a low-prevalence area (TF1–9 between 5–10 %). It is
possible that in a low-prevalence area the sensitivity of
TF and new pannus together as a diagnostic tool for Ct
infection would be improved relative to TF alone.
Conclusions
In communities where the prevalence of TF and Ct in-
fection are known or suspected to be discordant, it may
be desirable to use a more specific clinical diagnostic
sign for Ct infection in order to prevent an overesti-
mation of the disease burden. The poor sensitivity of the
test however renders it inappropriate in a programmatic
context. There were significantly more Ct positive indi-
viduals with both TF and new pannus compared to indi-
viduals with TF alone, therefore a cost-efficient approach
for assessing whether to prematurely stop MDA in a
community might be to perform molecular Ct testing
only on samples from individuals presenting with both
clinical signs. Early implementation of the ‘stopping rule’
based on testing a sample of individuals most likely to
have Ct infection, or, as we move towards elimination,
treating just this sample of individuals most likely to
have Ct infection, could lead to significant cost-savings
without loss of treatment impact.
Consent to publish
Written informed consent was obtained to publish anon-
ymized individual-level clinical data and images.
Fig. 1 Clinical grading of corneal pannus: example photographs. a Normal healthy cornea, b new pannus and c old pannus. Arrows point to the
lack of vascularization in controls a, neovascularization in new pannus b and old scarred vessels that indicate old pannus c
Table 2 Multivariable logistic regression of the relationship
between clinical phenotypes and Ct infection
P value aOR
a (2.5–97.5 % CIb)
TF 1.16 x 10−7 18.17 (6.73–59.5)
Pannus: New 0.0088 3.65 (1.4–9.8)
Pannus: Old 0.859 0.89 (0.23–3.26)
Gender (Male) 0.738 0.86 (0.35–2.08)
Age (years) 0.053 1.23 (1–1.52)
Model AIC (Akaike Information Criterion) is 143.46
a
aOR: Adjusted Odds Ratio (adjusted for all other variables in the model
as listed)
b CI Confidence Interval
Table 3 Performance of TF and new pannus as a diagnostic
test for Ct infection
TF New pannus TF & new pannus
Sensitivity 90.4 55.8 51.9
Specificity 69.7 85.3 91.7
PPV 58.8 64.4 75.0
NPV 93.8 80.2 80.0
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